Cell Source is selling for under 0.88 as of the 31st of January 2026; that is 1.12 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.88. Cell Source has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. The performance scores are derived for the period starting the 2nd of November 2025 and ending today, the 31st of January 2026. Click here to learn more.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 35.25 M outstanding shares. More on Cell Source
Cell Source [CLCS] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cell Source's market, we take the total number of its shares issued and multiply it by Cell Source's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cell Source conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 35.25 M outstanding shares.
Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations.
Check Cell Source Probability Of BankruptcyOwnership AllocationCell Source holds a total of 35.25 Million outstanding shares. Cell Source retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cell Ownership Details
About 32.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.2. Cell Source had not issued any dividends in recent years. Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.The quote for Cell Source is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Cell Source please contact Itamar Shimrat at 646 416 7896 or go to https://www.cell-source.com.
Cell Source has some characteristics of a very speculative penny stock
Cell Source appears to be risky and price may revert if volatility continues
Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (5.47 M) with profit before overhead, payroll, taxes, and interest of 0.
Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations.
Roughly 32.0% of the company shares are held by company insiders
Cell Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.61 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cell Source's market, we take the total number of its shares issued and multiply it by Cell Source's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Technical Drivers
As of the 31st of January, Cell Source shows the Downside Deviation of 8.52, risk adjusted performance of 0.1753, and Mean Deviation of 4.71. Cell Source technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cell Sourcedownside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Cell Source is priced correctly, providing market reflects its regular price of 0.88 per share. Given that Cell Source is a hitting penny stock territory we recommend to closely look at its total risk alpha.
The output start index for this execution was zero with a total number of output elements of sixty-one. Cell Source Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Cell Source price patterns.
Cell Source Outstanding Bonds
Cell Source issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cell Source uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cell bonds can be classified according to their maturity, which is the date when Cell Source has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Cell Source intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cell Source pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cell Source's time-series forecasting models are one of many Cell Source's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cell Source's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Our tools can tell you how much better you can do entering a position in Cell Source without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Global Correlations Now
Global Correlations
Find global opportunities by holding instruments from different markets
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.